Prospective validation of stringent dose constraints for prostatic stereotactic radiation monotherapy: results of a single-arm phase II toxicity-oriented trial.

Fiche publication

Date publication

août 2021

Journal

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Auteurs

Membres identifiés du Cancéropôle Est :
Dr RETIF Paul

Tous les auteurs :
Nguyen P, Harzée L, Retif P, Joseph S, Vogin G, Nickers P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34424351

Résumé

There are no safety-focused trials on stereotactic body radiotherapy (SBRT) for localized prostate cancer. This prospective 3‑year phase II trial used binomial law to validate the safety and efficacy of SBRT with stringent organ at risk dose constraints that nevertheless permitted high planning target volume doses.